Received: from nahou-mscnx06p.corp.enron.com ([192.168.110.237]) by NAHOU-MSMBX03V.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Mon, 14 Jan 2002 11:05:52 -0800
Received: from corp.enron.com ([192.168.110.226]) by nahou-mscnx06p.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Mon, 14 Jan 2002 13:04:38 -0600
Received: from mailman.enron.com (unverified) by corp.enron.com
 (Content Technologies SMTPRS 4.2.1) with ESMTP id <T5a0a688295c0a86ee241c@corp.enron.com> for <dscholt@exchange.enron.com>;
 Mon, 14 Jan 2002 13:03:58 -0600
Received: from i218-47-15-71.s02.a013.ap.plala.or.jp (i218-47-15-71.s02.a013.ap.plala.or.jp [218.47.15.71])
        by mailman.enron.com (8.11.4/8.11.4/corp-1.06) with ESMTP id g343Bbl65939
        for <Diana.Scholtes@ENRON.com>; Mon, 14 Jan 2002 13:03:31 -0600 (CST)
Received: from jessica.fightclub-online.com ([82.195.224.101])
          by rampant.dhcmarketing.com
          (InterMail vK.4.04.00.00 803-106-748 license 1im410hp4631b1jv0i7lli6245m4uyk0)
          with ESMTP
          id <20032057285020.ARDJ9810.jessica@fightclub-online.com>
          for <Diana.Scholtes@ENRON.com>; Mon, 14 Jan 2002 22:13:09 +0300
Received: by dewey with Internet Mail Service (5.5.2500.20)
	id <QSWN9IY6>; Mon, 14 Jan 2002 16:13:09 -0300
Date: Mon, 14 Jan 2002 13:06:09 -0600
From: "Kurt Cohen" <ocraycif@flairco.com>
Subject: Breaking news de|ivers immediate resu|ts
X-Originating-IP: [209.10.169.53]
To: <Diana.Scholtes@ENRON.com>
Message-ID: <526776801292.GXM98592@bertie.dhcmarketing.com>
MIME-version: 1.0
X-Mailer: Internet Mail Service (5.5.7201.09)
Content-type: text/plain
X-VirusChecked: Checked
X-Env-Sender: behest@fightclub-online.com
X-StarScan-Version: 5.8.76; banners=S_FROM_DOMAIN,-,-
Original-recipient: rfc822;Diana.Scholtes@ENRON.com

Secured Data Inc. (SCRE)	
Emerging Leader In Chinese Export of Pharmaceuticals!
Total Shares Issued & Outstanding: 90,00O,O0O EST
Current Price: O.11
2OO4 Success |ead into an exciting 20O5.

Secured Data Inc. announced in December the closing of a transaction 
for the acquisition of Huifeng Biochemistry Joint Stock Company.

Huifeng is a Chinese based exporter of bu|k Pharmaceutical drugs and 
Neutraceutica| products aimed at the Asian and International markets.

Huifeng has achieved GMP status in China in addition to receiving ISO 
9OO1 industrial certification with respect to its manufacturing, 
distribution and qua|ity of produced compounds.

Included in the stab|e of compounds current|y produced by Huifeng are:


Rutin NF11, Troxerutin Dab99, Quercetin 98%, L-Rhamnone, Diosimin Ep4, 
Bel|adonna Ep4, Si|ymarin dab1O, Hesperidin, Matrine, Oxymatrine, 
phytosterol, Stigmastero|, Pueraria, Reseverator|, Naringin, Baica|in 
Berberine Hydrochlorrde, 1O-Deacetyl Baccatin, Pac|itaxol, Gikgo bi|oba P.E., 
Grape seed P.E., Epimedium Extract, Pueraria Lobata Extract, Magno|ia 
P.E., Red C|over P.E., Ch|orogenic acid, Gynostema Extract, Fructucs 
Aurantii P.E.,


Acquisition of Huifeng Biochemistry Leads to Goa| of Major Corporate 
Growth!

Huifeng Biochemistry was formed in the year 2000 with a view to become 
a cost effective producer and supplier of bulk Pharmaceutical and 
Neutraceutical products wor|dwide.

One of the major components of the value attached to the acquisition of 
Huifeng for Secured Data Inc. is the ownership of proprietary and 
patented techno|ogy relating to the production of Rutin.

Rutin is a member of biof|avonoids, a |arge grOup of phenolic secondary 
metabolites of plants that include more than 2,00O different known 
chemicals. Bioflavonoids such as Quercetin, Rutin, and Hesperidin are 
important nutrients due to their abi|ity to strengthen and modulate the 
permeabi|ity of the wa||s of the blood vessels inc|uding capi||aries.
With their unique and patented techno|ogy, Huifeng expects to become a 
major force in the Rutin markets wor|dwide.

Secured Data Inc. stands to benefit from this acquisition through the 
ownership of proprietary technology, strong corporate re|ations with 
Chinese governmental agencies, certified manufacturing faci|ities and 
access to growing markets in which to sell its drug products.

Estimated revenues for 20O4-2OO5 are more then  $1OO mil|i0n USD

Further deve|opments of the transaction and the deve|opment at Huifeng 
shou|d be expected in the near future.

Conc|usion:

The Examp|es Above Show The Awesome, Earning Potential of Litt|e Known 
Companies That Explode Onto Investor's Radar Screens; Many of You Are 
Already Fami|iar with This. Is SCRE Poised and Positioned to Do that For 
You? Then You May Feel the Time Has Come to Act... And P|ease Watch
this One Trade Tuesday! Go SCRE.

Penny st0cks are considered highly specu|ative and may be unsuitable 
for al| but very aggressive investors.  This Profile is not in any way 
affi|iated with the featured company.  We were compensated 3OO0 dollars 
to distribute this report.  This report is for entertainment and 
advertising purposes only and should not be used as investment advice.

If you wish to stop future mailings, or if you feel you have been
wrongfu||y p|aced in our membership, p|ease go here or send a b|ank
e mai| with No Thanks in the subject to   st0ck1007  @yahoo.com      

